A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

NCT02637531 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors (Part A/B/C/D)
Non-small Cell Lung Cancer (Part E)
Melanoma (Part E)
Squamous Cell Cancer of the Head and Neck (Part E)
Triple Negative Breast Cancer (Part F)
Adrenocortical Carcinoma (Part G)
Mesothelioma (Part G)
High-circulating Myeloid-derived Suppressor Cells (Part H)

Interventions

DRUG: IPI-549 (eganelisib)
DRUG: Nivolumab

Sponsor

Infinity Pharmaceuticals, Inc.